Petros Pharmaceuticals, Inc. Financing Cash Flow
Petros Pharmaceuticals, Inc. (PTPI) reported Financing Cash Flow of $8.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$117.31K.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was -$428.23K.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $8.71M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $8.16M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$7.00M, a 160.67% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $11.54M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$1.62M, a 108.75% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$117.31K derived: sum of 2 quarters · filed 2026-04-15 | -$545.54K derived: sum of 3 quarters · filed 2026-08-13 | $8.16M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$117.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$545.54K derived: sum of 2 quarters · filed 2026-08-13 | $8.16M 10-Q · filed 2025-11-13 | $7.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$428.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $8.28M 10-Q · filed 2026-08-13 | $7.13M derived: sum of 3 quarters · filed 2026-08-13 | $4.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $8.71M 10-Q · filed 2026-05-13 | $7.56M derived: sum of 2 quarters · filed 2026-05-13 | $4.79M derived: sum of 3 quarters · filed 2026-05-13 | $2.83M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$3.92M derived: sum of 2 quarters · filed 2026-04-15 | -$5.88M derived: sum of 3 quarters · filed 2026-04-15 | -$7.00M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.73M derived: sum of 2 quarters · filed 2025-11-13 | -$5.85M 10-Q · filed 2025-11-13 | -$8.23M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.08M 10-Q · filed 2025-08-14 | -$5.45M derived: sum of 3 quarters · filed 2025-08-14 | $9.18M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.12M 10-Q · filed 2025-05-15 | -$3.49M derived: sum of 2 quarters · filed 2025-05-15 | $11.14M derived: sum of 3 quarters · filed 2025-05-15 | $10.77M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $12.26M derived: sum of 2 quarters · filed 2025-03-31 | $11.90M derived: sum of 3 quarters · filed 2025-03-31 | $11.54M 10-K · filed 2025-03-31 |
| 2023-09-30 | $14.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $14.27M derived: sum of 2 quarters · filed 2024-11-13 | $13.91M 10-Q · filed 2024-11-13 | $13.73M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$363.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$721.03K 10-Q · filed 2024-08-14 | -$906.09K derived: sum of 3 quarters · filed 2024-08-14 | -$1.27M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$357.83K 10-Q · filed 2024-05-15 | -$542.89K derived: sum of 2 quarters · filed 2024-05-15 | -$904.84K derived: sum of 3 quarters · filed 2024-05-15 | -$1.08M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$185.06K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$547.01K derived: sum of 2 quarters · filed 2024-04-01 | -$723.98K derived: sum of 3 quarters · filed 2024-04-01 | -$1.62M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$361.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$538.92K derived: sum of 2 quarters · filed 2023-11-15 | -$1.44M 10-Q · filed 2023-11-15 | $22.58M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | -$176.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.08M 10-Q · filed 2023-08-14 | $22.94M derived: sum of 3 quarters · filed 2023-08-14 | $21.26M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$900.00K 10-Q · filed 2023-05-15 | $23.12M derived: sum of 2 quarters · filed 2023-05-15 | $21.43M derived: sum of 3 quarters · filed 2023-05-15 | $19.80M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $24.02M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $22.33M derived: sum of 2 quarters · filed 2023-03-31 | $20.70M derived: sum of 3 quarters · filed 2023-03-31 | $18.57M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$1.68M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$3.32M derived: sum of 2 quarters · filed 2022-11-15 | -$5.45M 10-Q/A · filed 2022-11-15 | $15.55M derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$3.76M 10-Q · filed 2022-08-12 | $17.23M derived: sum of 3 quarters · filed 2022-08-12 | $19.74M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$2.13M 10-Q · filed 2022-05-16 | $18.87M derived: sum of 2 quarters · filed 2022-05-16 | $21.37M derived: sum of 3 quarters · filed 2022-05-16 | $26.80M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $20.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $23.50M derived: sum of 2 quarters · filed 2022-03-31 | $28.93M derived: sum of 3 quarters · filed 2022-03-31 | $30.30M 10-K · filed 2022-03-31 |
| 2020-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $7.93M derived: sum of 2 quarters · filed 2021-11-15 | $9.31M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $6.81M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $1.38M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |